Research ArticleMetabolism, Transport, and Pharmacogenomics
Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I
Shelby Barnett, Kayode Ogungbenro, Karelle Ménochet, Hong Shen, W. Griffith Humphreys and Aleksandra Galetin
Journal of Pharmacology and Experimental Therapeutics January 2019, 368 (1) 125-135; DOI: https://doi.org/10.1124/jpet.118.253062
Shelby Barnett
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, United Kingdom (S.B., K.O., A.G.); Non-Clinical PKPD, UCB, Slough, United Kingdom (K.M.); and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (H.S., W.G.H.)
Kayode Ogungbenro
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, United Kingdom (S.B., K.O., A.G.); Non-Clinical PKPD, UCB, Slough, United Kingdom (K.M.); and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (H.S., W.G.H.)
Karelle Ménochet
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, United Kingdom (S.B., K.O., A.G.); Non-Clinical PKPD, UCB, Slough, United Kingdom (K.M.); and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (H.S., W.G.H.)
Hong Shen
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, United Kingdom (S.B., K.O., A.G.); Non-Clinical PKPD, UCB, Slough, United Kingdom (K.M.); and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (H.S., W.G.H.)
W. Griffith Humphreys
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, United Kingdom (S.B., K.O., A.G.); Non-Clinical PKPD, UCB, Slough, United Kingdom (K.M.); and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (H.S., W.G.H.)
Aleksandra Galetin
Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, United Kingdom (S.B., K.O., A.G.); Non-Clinical PKPD, UCB, Slough, United Kingdom (K.M.); and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, New Jersey (H.S., W.G.H.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleMetabolism, Transport, and Pharmacogenomics
Comparison of OATP1B Biomarkers against Rosuvastatin and CPI
Shelby Barnett, Kayode Ogungbenro, Karelle Ménochet, Hong Shen, W. Griffith Humphreys and Aleksandra Galetin
Journal of Pharmacology and Experimental Therapeutics January 1, 2019, 368 (1) 125-135; DOI: https://doi.org/10.1124/jpet.118.253062
Research ArticleMetabolism, Transport, and Pharmacogenomics
Comparison of OATP1B Biomarkers against Rosuvastatin and CPI
Shelby Barnett, Kayode Ogungbenro, Karelle Ménochet, Hong Shen, W. Griffith Humphreys and Aleksandra Galetin
Journal of Pharmacology and Experimental Therapeutics January 1, 2019, 368 (1) 125-135; DOI: https://doi.org/10.1124/jpet.118.253062
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement